The vaccine trial is on track. Last Friday, on 9 October, the first test subject was injected with the vaccine MVA-SARS-2-S against COVID-19. A total of six volunteers received the vector vaccine to
Please use this picture only in connection with the press release.
The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, today approved the clinical trial of the MVA-SARS-2-S vaccine against COVID-19. The vector vaccine was developed by
An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have great potential to be used for
At the DZIF, EBV research has been ongoing for years. Now a promising vaccine candidate is passing from the laboratory to quality assured production. Subsequently, preclinical and early clinical
The production of a vaccine against the harmful MERScoronavirus is funded by the international vaccine initiative CEPI (Coalition for Epidemic Preparedness Innovations) with up to 36 million dollars
Dr Christian Keller, from Philipps-University Marburg and the German Center for Infection Research, and Dr Anke Osterloh, Research Center Borstel, were awarded this year’s "Memento Award for neglected
